WO2017185038A1 - Fast-acting plant-based medicinal compounds and nutritional supplements - Google Patents

Fast-acting plant-based medicinal compounds and nutritional supplements Download PDF

Info

Publication number
WO2017185038A1
WO2017185038A1 PCT/US2017/028953 US2017028953W WO2017185038A1 WO 2017185038 A1 WO2017185038 A1 WO 2017185038A1 US 2017028953 W US2017028953 W US 2017028953W WO 2017185038 A1 WO2017185038 A1 WO 2017185038A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
based composition
disease
cannabis
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/028953
Other languages
English (en)
French (fr)
Inventor
Andrea Leone-Bay
Gregory WESNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptor Life Sciences
Original Assignee
Receptor Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60117058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2017185038(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2017252575A priority Critical patent/AU2017252575B2/en
Priority to EP17786760.3A priority patent/EP3445356B1/en
Priority to CA3021660A priority patent/CA3021660A1/en
Priority to EA201892396A priority patent/EA201892396A1/ru
Priority to KR1020187033084A priority patent/KR102393596B1/ko
Priority to BR112018071518-2A priority patent/BR112018071518A2/pt
Priority to US16/094,802 priority patent/US10588974B2/en
Priority to CN201780024997.6A priority patent/CN109069475B/zh
Priority to EP21175803.2A priority patent/EP3928776B1/en
Priority to JP2019506612A priority patent/JP6983868B2/ja
Application filed by Receptor Life Sciences filed Critical Receptor Life Sciences
Priority to MX2018012913A priority patent/MX382853B/es
Publication of WO2017185038A1 publication Critical patent/WO2017185038A1/en
Priority to IL262505A priority patent/IL262505B/en
Priority to CONC2018/0011299A priority patent/CO2018011299A2/es
Anticipated expiration legal-status Critical
Priority to US16/805,356 priority patent/US11129897B2/en
Priority to US17/409,417 priority patent/US20230075677A1/en
Priority to JP2021189167A priority patent/JP7284241B2/ja
Priority to IL290084A priority patent/IL290084A/en
Priority to AU2022201021A priority patent/AU2022201021B2/en
Priority to US18/461,125 priority patent/US20240261408A1/en
Priority to AU2024200704A priority patent/AU2024200704A1/en
Priority to US19/299,150 priority patent/US20250367295A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the current disclosure provides fast-acting plant-based medicinal compounds or nutritional supplements in various carrier combinations.
  • the carriers can include /V-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers.
  • the plant-based composition/carrier combinations can create administration benefits following oral administration.
  • Calophyllum is a flowering plant genus of around 180-200 species of tropical evergreen trees.
  • the Calophyllum genus includes four subcategories: Calophyllum brasiliense, Calophyllum caledonicurn, Calophyllum inophyllum and Calophyllum soulattri.
  • Calophyllum inophyllum is a medium to large sized evergreen tree that averages 25-65 feet in height.
  • Different medicinal uses of this plant have been reported in the literature, for example, decoction of the bark of this plant treats internal hemorrhages.
  • the oil extracted from Calophyllum inophyllum seeds is used to treat rheumatoid arthritis or joint disorders; itching; eczema; pimples appearing on head; eye diseases; and kidney failure.
  • U.S. Publication No. 2014/0193345 describes use of the plants Uncaria tomentosa, Thymus vulgaris, Matricaria recutita, Salix alba, Calendula officinalis, Usnea barbata, Ligusticum portieri-osha, Gaultheria procumbens, Camellia sinensis, Vaccinium myrtillus, Melissa officinalis, Allium sativum, Camellia sinensis and Krameria triandra to treat mucosal lesions.
  • THC delta-9-tetrahydrocannabinol
  • Dronabinol an extract of the cannabis plant has been formulated in sesame oil for oral delivery.
  • CNS central nervous system
  • THC has been shown to have a marked appetite stimulant effect and has been used in the treatment of AIDS-related anorexia.
  • THC demonstrates effects on appetite, mood, cognition, memory and perception.
  • the drug has anti-emetic properties and is used to control nausea and vomiting associated with cancer chemotherapy. These effects appear to be dose related.
  • THC has also been reported to be an antiemetic and anxiolytic, and also useful for treating pain of various etiologies such as multiple sclerosis (MS), peripheral neuropathy and spinal injuries (Lancet, 1995, 345, 579, Pharm. J. 259, 104, 1997; Baker & Pryce, Expert Opin Investig Drugs. 2003 Apr; 12(4): 561-7)).
  • MS multiple sclerosis
  • THC has also been reported to be useful in the treatment of AIDS (J. Pain. Symptom Manage. 1995, 10, 89-97) when given orally.
  • CBD cannabidiol
  • antidepressant Zanelati T, et al. Journal of Pharmacology. 2010. 159(1): 122-8;
  • anti-anxiety Resstel BM, et al. Br J Pharmacol. 2009. 156(1): 181-188
  • anti-inflammatory Vuolo F, et al. Mediators of Inflammation. 2015. 538670
  • neuroprotective effects Campos AC, et al. Pharmacol Res. 2016. 1 12:1 19-127).
  • the cannabis plant includes treating acquired hypothyroidism, acute gastritis, agoraphobia, ankyloses, arthritis, Asperger's syndrome, atherosclerosis, autism, bipolar disorder, blood disorders, cachexia, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy, fever, fibromyalgia, flu, fungal infection, gastrointestinal disorders, glaucoma, glioma, Grave's disease, hepatitis, herpes, hypertension, impotence, incontinence, infant mortality, inflammatory bowel disease (IBD), insomnia, liver fibrosis, mad cow disease, menopause, migraine headaches, motion sickness, MRSA, muscular dystrophy, nail patella syndrome, neuroinflamm
  • THC has an onset of action of fifteen minutes at the very earliest to 1.5 hours and a peak effect at 2-4 hours.
  • the duration of action for psychoactive effects is 4-6 hours, but the appetite stimulant effect may continue for 24 hours or longer after administration.
  • THC is almost completely absorbed (90-95%) after single oral doses.
  • THC water solubility is 2.8mg/L
  • oral consumption of cannabis is characterized by low bioavailability of cannabinoids, and slow onset of action.
  • the current disclosure provides fast-acting plant-based medicinal compounds and nutritional supplements (collectively, plant-based compositions) formulated for oral delivery. By providing fast-acting delivery, physiological benefits are observed earlier increasing the usefulness of these compounds.
  • the disclosed fast-acting plant-based compositions can create various administration benefits in providing therapeutically effective amounts in a variety of conditions.
  • exemplary administration benefits include increased absorption, increased bioavailability, faster onset of action, higher peak concentrations, faster time to peak concentrations, shorter duration of action, increased subjective therapeutic efficacy, and increased objective therapeutic efficacy.
  • the fast-acting nature of the plant-based compositions is created by including one or more /V-acylated fatty amino acids, absorption enhancing agents, and/or various other beneficial carriers, such as surfactants, detergents, azones, pyrrolidones, glycols and bile salts in an oral formulation.
  • /V-acylated fatty amino acids can be linear, branched, cyclic, bicyclic, or aromatic including, for example, 1-50 carbon atoms in an oral formulation. That use of /V-acylated fatty amino acids could provide a fast-acting benefit with a plant-based composition was unexpected given particular aspects of plant-based components described further herein.
  • the ability of /V-acylated fatty amino acids to increase absorption of compounds is proportional to the water-solubility of a compound.
  • Many plant-based compounds are not water-soluble and would not have been expected to be affected by the presence of an N- acylated fatty amino acid.
  • the plant-based compositions include Calophyllum brasiliense, Calophyllum caledonicurn, Calophyllum inophyllum, Calophyllum soulattri, Uncaria tomentosa, Thymus vulgaris, Matricaria recutita, Salix alba, Calendula officinalis, Usnea barbata, Ligusticum portieri-osha, Gaultheria procumbens, Camellia sinensis, Vaccinium myrtillus, Melissa officinalis, Allium sativum, Camellia sinensis, Krameria triandra, Punica granatum, Viburnum plicatum, Nicotiana tabacum, Duboisia hopwoodii, Asclepias syriaca, Curcuma longa, Cannabis sativa, Cannabis indica, Cannabis ruderalis, and Acer spp., or an extract thereof.
  • Calophyllum brasiliense Calophy
  • FIG. 1A shows the multiple of improvement from SNAC plotted for cromolyn, vitamin B12, atorvastatin, and ibandronate, along with the aqueous solubility of each molecule.
  • FIG. 1A shows the multiple of improvement from SNAC plotted for cromolyn, vitamin B12, atorvastatin, and ibandronate, along with the aqueous solubility of each molecule.
  • FIG. 1 B plots the aqueous solubility of heparin, acyclovir, rhGH, PTH, MT-II, GLP-1 , calcitonin, yy peptide, and THC according to the logarithmic trendline derived from FIG. 1A.
  • FIG. 2 provides exemplary cannabinoid structures.
  • FIG. 3 provides modified amino acids of compounds l-XXXV.
  • FIG. 4 provides fatty acid amino acids of formula (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (I), (m), (n), (o), (p), (q), and (r), wherein R1 is an alkyl group including 5 to 19 carbon atoms, R2 is H (i.e. hydrogen) or CH3 (i.e. methyl group), and R3 is H; or a salt or the free acid form thereof.
  • FIGs. 5A and 5B provide the average results of the study comparing onset and duration of action of orally administered cannabis//V-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC, "test”) formulation and cannabis (without SNAC, "control”) formulation.
  • FIGs. 6A-6F provide the results for each individual participant in the study comparing onset and duration of action of orally administered cannabis//V-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC, "test”) formulation and cannabis (without SNAC, "control”) formulation.
  • FIG. 7 shows a comparison of intensity, duration and onset of action of orally administered cannabis formulations with a high SNAC dose (200mg, "high dose”), a low SNAC dose (100mg, "low dose”) and no SNAC ("control").
  • FIG. 8 shows intensity, duration and onset of action of cannabis formulated with SNAC administered orally ("PO") compared to cannabis administered by inhalation (“INH").
  • THC has an onset of action of fifteen minutes at the very earliest to 1.5 hours and a peak effect at 2-4 hours.
  • the duration of action for psychoactive effects is 4-6 hours, but the appetite stimulant effect may continue for 24 hours or longer after administration.
  • THC is almost completely absorbed (90-95%) after single oral doses.
  • THC water solubility is 2.8mg/L
  • oral consumption of cannabis is characterized by low bioavailability of cannabinoids, and slow onset of action.
  • the current disclosure provides fast-acting plant-based medicinal compounds and nutritional supplements (collectively, plant-based compositions) formulated for oral delivery. By providing fast-acting delivery, physiological benefits are observed earlier increasing the usefulness of these compounds.
  • the disclosed fast-acting plant-based compositions can create various administration benefits in providing therapeutically effective amounts in a variety of conditions.
  • exemplary administration benefits include increased absorption, increased bioavailability, faster onset of action, higher peak concentrations, faster time to peak concentrations, shorter duration of action, increased subjective therapeutic efficacy, and increased objective therapeutic efficacy.
  • the fast-acting nature of the plant-based compositions is created by including one or more /V-acylated fatty amino acids, absorption enhancing agents, and/or various other beneficial carriers, such as surfactants, detergents, azones, pyrrolidones, glycols and bile salts in an oral formulation.
  • /V-acylated fatty amino acids can be linear, branched, cyclic, bicyclic, or aromatic including, for example, 1-50 carbon atoms in an oral formulation. That use of /V-acylated fatty amino acids could provide a fast-acting benefit with a plant-based composition was unexpected given particular aspects of plant-based components described further herein.
  • the ability of /V-acylated fatty amino acids to increase absorption of compounds is proportional to the water-solubility of a compound.
  • Many plant-based compounds are not water-soluble and would not have been expected to be affected by the presence of an N- acylated fatty amino acid.
  • Molecules that have been shown to have improved absorption when co-administered with an /V-acylated fatty amino acid (e.g., SNAC) include water-soluble molecules such as cromolyn, vitamin B12), atorvastatin, ibandronate, heparin, acyclovir, recombinant human growth hormone (rhGH), parathyroid hormone 1-34 (PTH 1-34), a-melanotropin (MT-II), GLP-1 , calcitonin, and peptide yy.
  • water-soluble molecules such as cromolyn, vitamin B12), atorvastatin, ibandronate, heparin, acyclovir, recombinant human growth hormone (rhGH), parathyroid hormone 1-34 (PTH 1-34), a-melanotropin (MT-II), GLP-1 , calcitonin, and peptide yy.
  • FIG. 1A shows an established correlation between water-solubility and the ability of SNAC to improve a molecule's absorption.
  • AUC area under the curve
  • a multiple of improvement can be calculated by dividing the AUC for a molecule with SNAC by the AUC for the molecule without SNAC.
  • FIG. 1A shows the multiple of improvement from SNAC plotted for cromolyn, vitamin B12, atorvastatin, and ibandronate, along with the aqueous solubility of each molecule.
  • Heparin, acyclovir, rhGH, PTH, MT-II, GLP-1 , calcitonin, and yy peptide are other molecules have been shown to have SNAC-improved absorption, as demonstrated by Cmax (maximum drug plasma level) and/or Tmax (the time taken to reach maximum drug plasma level).
  • Cmax maximum drug plasma level
  • Tmax the time taken to reach maximum drug plasma level
  • each of these molecules has an aqueous solubility of more than 0.15 mg/ml, and therefore, the model accurately predicts that SNAC can improve their absorption. This result demonstrates that a SNAC-based absorption improvement correlates with a molecule's aqueous solubility.
  • Plant-based compositions refer to plant-based medicinal compounds and plant-based nutritional supplements.
  • Plant-based medicinal compounds provide therapeutically-effective amounts to treat a condition, such as those described in the Background of the Disclosure.
  • Plant-based nutritional supplements claim a benefit related to a classical nutrient deficiency; describes how the supplement is intended to affect the structure or function of the human body; characterizes a documented mechanism by which the supplement acts to maintain such structure or function; and/or describes general well- being associated with consumption of the product.
  • a nutritional supplement may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases.
  • Plant-based compositions include vegetable matter. Vegetable matter is matter produced by a plant and includes any whole plant or plant part (e.g., bark, wood, leaves, stems, roots, flowers, fruits, seeds, or parts thereof) and/or exudates or extracts thereof.
  • plant-based compositions include botanical products. Botanical products can include plant materials, algae, macroscopic fungi, and/or combinations thereof.
  • plant-based compositions include a mixture of various types of vegetable matter. Plant-based compositions can also include materials derived from vegetable matter including resins, oils, dried flowers, kief, tinctures, infusions, etc. In particular embodiments, the vegetable matter has little or no water solubility. In particular embodiments, plant-based compositions do not include synthetic, semi-synthetic, or chemically-modified drugs.
  • the plant-based compositions include vegetable matter derived from Calophyllum brasiliense, Calophyllum caledonicurn, Calophyllum inophyllum, Calophyllum soulattri, Uncaria tomentosa, Thymus vulgaris, Matricaria recutita, Salix alba, Calendula officinalis, Usnea barbata, Ligusticum portieri-osha, Gaultheria procumbens, Camellia sinensis, Vaccinium myrtillus, Melissa officinalis, Allium sativum, Camellia sinensis, Krameria triandra, Punica granatum, Viburnum plicatum, Nicotiana tabacum, Duboisia hopwoodii, Asclepias syriaca, Curcuma longa, Cannabis sativa, Cannabis indica, Cannabis ruderalis and/or Acer spp. or an extract thereof
  • the plant-based compositions include vegetable matter derived from the cannabis plant.
  • the cannabis plant refers to a flowering plant including the species (or sub-species) Cannabis sativa, Cannabis ruderalis, and Cannabis indica.
  • Cannabinoids are a group of cyclic molecules from cannabis plants that activate cannabinoid receptors (i.e., CB1 and CB2) in cells. There are at least 85 different cannabinoids that can be isolated from cannabis. Many cannabinoids produced by cannabis plants, such as A9-Tetrahydrocannabinol (THC) and cannabidiol (CBD), have very low or no solubility in water. The most notable cannabinoids are THC and CBD.
  • THC A9-Tetrahydrocannabinol
  • CBD cannabidiol
  • Extracts of the cannabis plant similarly include flavonoid compounds, terpenes, terpenoid, and synthetic, semisynthetic or highly purified
  • Extracts of plant-based compositions can be produced by, e.g. , pulverization, decoction, expression, and extraction of a starting plant product.
  • extract can include all of the many types of preparations containing some or all of the active ingredients found in the relevant plants. Extracts may be produced by cold extraction techniques using a variety of different extraction solvents including water, fatty solvents (such as olive oil), and alcoholic solvents (e.g. 70% ethanol). Cold extraction techniques are typically applied to softer parts of the plant such as leaves and flowers, or in cases wherein the desired active components of the plant are heat labile.
  • the aforementioned solvents may be used to produce extracts of the desired plants by a hot extraction technique, wherein said solvents are heated to a high temperature, the precise value of said temperature being dependent on the properties of the chosen solvent, and maintained at that temperature throughout the extraction process.
  • Hot extraction techniques are more commonly applied to the harder, tougher parts of the plant, such as bark, woody branches and larger roots.
  • sequential extractions can be performed in more than one solvent, and at different temperatures.
  • the plant extract may be used in a concentrated form. Alternatively, the extract may be diluted as appropriate to its intended use.
  • WO2004/026857 provides a method for preparing a purified cannabis extract, wherein the cannabinoids are purified to at least 99% wt % THC ⁇ -tetrahydrocannabinol).
  • a crude ethanolic extract of Cannabis plant material is passed through a column of activated charcoal and evaporated by means of rotary evaporation.
  • the resulting THC enriched extract is subsequently passed through a column packed with Sephadex LH20 and eluted with chloroform/dichloromethane.
  • the solvent used is removed by means of rotary evaporation.
  • the extract is dissolved in methanol and subsequently in pentane and subjected to rotary evaporation twice.
  • US2015/0126754 describes a) providing a crude solvent extract of Cannabis plant material; b) subjecting the crude extract to thin film evaporation to obtain a refined extract; c) chromatographically fractionating the refined extract to produce one or more high purity fractions having a THC content higher than a preset value and one or more low purity fractions having a THC content lower than the preset value, wherein the preset value is in the range of 95-99% by weight of dry matter; d) subjecting the one or more high purity fractions to another thin film evaporation; and e) collecting a THC isolate containing at least 97% THC by weight of dry matter; and wherein in step b) and/or in step d) the thin film evaporation is carried out by using wiped film evaporation.
  • This method offers the advantage that it yields a high purity THC extract in good yield and without using solvents that pose a health risk.
  • the method further offers the advantage that it is highly reproducible in that it produces THC-isolate with a specific cannabinoid profile. More particularly, the method yields a THC isolate that contains at least 97.0-99.5% THC and 0.4- 2.0% of other cannabinoids, including at least 0.3% Cannabinol and Cannabidiol (all percentages by weight of dry matter).
  • plant components of plant-based compositions may be sterilized, for example by autoclaving, and then allowed to cool and stored at an appropriate temperature (e.g., -20°C).
  • an appropriate temperature e.g., -20°C
  • further purification to a molecular weight cut-off e.g., below 10,000 Da
  • membrane ultrafiltration e.g., by membrane ultrafiltration before storage.
  • plant-based compositions include carriers such as modified amino acids, a surfactant, a detergent, an azone, a pyrrolidone, a glycol, or a bile salt.
  • An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring, non-naturally occurring and synthetic amino acids.
  • Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked, e.g. an ester, anhydride, or an anhydride linkage.
  • Peptides are two or more amino acids joined by a peptide bond. Peptides can vary in length from dipeptides with two amino acids to poly peptides with several hundred amino acids. See Chambers Biological Dictionary, editor Peter M. B. Walker, Cambridge, England: Chambers Cambridge, 1989, page 215. Di-peptides, tri-peptides, tetra- peptides, and penta-peptides can also be used.
  • Carriers which are modified amino acids include acylated fatty acid amino acids (FA-aa) or a salt thereof, which are typically prepared by modifying the amino acid or an ester thereof by acylation or sulfonation.
  • Acylated fatty acid amino acids include /V-acylated FA-aa or an amino acid acylated at its alpha amino group with a fatty acid.
  • Exemplary /V-acylated fatty amino acid salts include sodium /V-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).
  • Other names for SNAC include Sodium-A/-salicyloyl-8-aminocapry!ate, Monosodium 8-(A/-salicyIoyiamino) octanoate, A/-(sa!icyloyl)-8-aminooctanoic acid monosodium salt, monosodium A/- ⁇ 8-(2-hydroxybenzoyl)amino ⁇ octanoate, or sodium 8-[(2- hydroxybenzoyl)amino]octanoate.
  • SNAC has the structure:
  • Salts of SNAC may also be used as a carrier.
  • Salts of SNAC include:
  • X and Z are independently H, a monovalent cation, a divalent metal cation, or an organic cation.
  • monovalent cations include sodium and potassium.
  • divalent cations include calcium and magnesium.
  • organic cations include ammonium and tetramethylammonium.
  • Exemplary modified amino acids such as /V-acylated FA-aas, are provided as compounds l-XXXV (see FIG. 3). Salts of these compounds and other /V-acylated FA-aa can also be used as carriers.
  • compounds l-VII are derived from aminobutyric acid.
  • compounds Vlll-X and XXXI-XXIIV are derived from aminocaproic acid.
  • compounds XI-XXVI and XXXV are derived from aminocaprylic acid.
  • the modified amino acid compounds above may be prepared by reacting the single amino acid with the appropriate modifying agent which reacts with free amino moiety present in the amino acids to form amides. Protecting groups may be used to avoid unwanted side reactions as would be known to those skilled in the art.
  • the amino acid can be dissolved in aqueous alkaline solution of a metal hydroxide, e.g., sodium or potassium hydroxide, and heated at a temperature ranging between 5° C. and 70° C, preferably between 0° C. and 40° C, for a period ranging between 1 hour and 4 hours, preferably 2.5 hours.
  • a metal hydroxide e.g., sodium or potassium hydroxide
  • the amount of alkali employed per equivalent of Nh groups in the amino acid generally ranges between 1.25 and 3 mmole, preferably between 1.5 and 2.25 mmoie per equivalent of NH 2 .
  • the pH of the solution generally ranges between 8 and 13, preferably ranging between 10 and 12.
  • the appropriate amino acid modifying agent is added to the amino acid solution while stirring.
  • the temperature of the mixture is maintained at a temperature generally ranging between 5° C. and 70° C, preferably between 10° C. and 40° C, for a period ranging between 1 and 4 hours.
  • the amount of amino acid modifying agent employed in relation to the quantity of amino acid is based on the moles of total free NH2 in the amino acid.
  • the amino acid modifying agent is employed in an amount ranging between 0.5 and 2.5 mole equivalents, preferably between 0.75 and 1.25 equivalents, per molar equivalent of total NH2 group in the amino acid.
  • the reaction is quenched by adjusting the pH of the mixture with a suitable acid, e.g., concentrated hydrochloric acid, until the pH reaches between 2 and 3.
  • a suitable acid e.g., concentrated hydrochloric acid
  • the mixture separates on standing at room temperature to form a transparent upper layer and a white or off-white precipitate.
  • the upper layer is discarded, and the modified amino acid is collected from the lower layer by filtration or decantation.
  • the crude modified amino acid is then dissolved in water at a pH ranging between 9 and 13, preferably between 1 1 and 13. Insoluble materials are removed by filtration and the filtrate is dried in vacuo.
  • the yield of modified amino acid generaliy ranges between 30 and 60%, and usually 45%.
  • amino acid esters such as, for example benzyl, methyl, or ethyl esters of amino acid compounds
  • the amino acid ester dissolved in a suitable organic solvent such as dimethyiformamide, pyridine, or tetrahydrofuran can be reacted with the appropriate amino acid modifying agent at a temperature ranging between 5° C. and 70° C, preferably 25° C, for a period ranging between 7 and 24 hours.
  • the amount of amino acid modifying agent used relative to the amino acid ester is the same as described above for amino acids.
  • This reaction may be carried out with or without a base such as, for example, triethyiamine or diisopropyiethylamine.
  • the reaction solvent is removed under negative pressure and the ester functionality is removed by hydrolyzing the modified amino acid ester with a suitable alkaline solution, e.g. 1 N sodium hydroxide, at a temperature ranging between 50° C. and 80° C, preferably 70° C, for a period of time sufficient to hydrolyze off the ester group and form the modified amino acid having a free carboxyl group.
  • a suitable alkaline solution e.g. 1 N sodium hydroxide
  • the hydrolysis mixture is then cooled to room temperature and acidified, e.g. aqueous 25% hydrochloric acid solution, to a pH ranging between 2 and 2.5.
  • the modified amino acid precipitates out of solution and is recovered by conventional means such as filtration or decantation.
  • Benzyl esters may be removed by hydrogenation in an organic solvent using a transition metal catalyst.
  • the modified amino acid may be purified by recrystallization or by fractionation on solid column supports.
  • Suitable recrystallization solvent systems include acetonitriie, methanol and tetrahydrofuran. Fractionation may be performed on a suitable solid column supports such as alumina, using methanoi/n-propanoi mixtures as the mobile phase; reverse phase column supports using trif!uoroacetic acid/acetonitriie mixtures as the mobile phase; and ion exchange chromatography using water as the mobile phase.
  • anion exchange chromatography preferably a subsequent 0-500 mM sodium chloride gradient is employed.
  • R 1 is C3 -C24 alkylene, C2 -C20 alkenylene, C2 -C20 alkynylene, cydoalkylene, or an aromatic, such as aryiene;
  • R 2 is hydrogen, Ci -C 4 a!ky!, or C2 -C 4 alkenyl
  • R 3 is Ci -C7 a!ky!, C3 -C10 cycioalkyl, aryi, thieny!, pyrrolo, or pyridyl, and
  • R 3 is optionally substituted by one or more Ci -C5 alky! group, C2 -C 4 alkenyl group, F, CI, OH, OR 1 , S0 2 , COOH, COOR or, S0 3 H;
  • a lactam as shown in the above formula can be prepared, for example by the method described in Olah et ai. , Synthesis, 537-538 (1979).
  • modified amino acids also include an amino acid acylated at its alpha amino group with a fatty acid, which can be represented by the general formula A-X, wherein A is the alpha-amino acid residue and X is a fatty acid attached by acylation to A's alpha- amino group.
  • the amino acids include cationic and non-cationic amino acids.
  • non-cationic amino acid refers to an amino acid selected from the group consisting of non-polar hydrophobic amino acids, polar non-charged amino acids, and polar acidic amino acids.
  • non-cationic amino acid refers to amino acids selected from the group consisting of Alanine (Ala), Valine (Val), Leucine (Leu), Isoleucine (lie), Phenylalanine (Phe), Tryptophane (Trp), Methionine (Met), Proline (Pro), Sarcosine, Glycine (Gly), Serine (Ser), Threonine (Thr), Cysteine (Cys), Tyrosine (Tyr), Asparagine (Asn), and Glutamine (Gin), Aspartic acid (Asp), and Glutamic acid [0058]ln particular embodiments, the acylated FA-aa includes an alpha amino acid residue of a non-polar hydrophobic amino acid.
  • the acylated FA-aa may be represented by the general formula A-X, wherein A is the amino acid residue of a non-polar hydrophobic amino acid and X is a fatty acid attached by acylation to A's alpha-amino group.
  • non-polar hydrophobic amino acid refers to categorisation of amino acids used by the person skilled in the art.
  • non-polar hydrophobic amino acid refers to an amino acid selected from the group consisting of Alanine (Ala), Valine (Val), Leucine (Leu), Isoleucine (lie), Phenylalanine (Phe), Tryptophane (Trp), Methionine (Met), Proline (Pro) and Sarcosine.
  • the acylated FA-aa includes the amino acid residue of a polar non-charged amino acid.
  • the acylated FA-aa may be represented by the general formula A-X, wherein A is the amino acid residue of a polar non-charged amino acid and X is a fatty acid attached by acylation to A's alpha-amino group.
  • A is the amino acid residue of a polar non-charged amino acid
  • X is a fatty acid attached by acylation to A's alpha-amino group.
  • the term "polar non-charged amino acid” as used herein refers to categorisation of amino acids used by the person skilled in the art.
  • polar non-charged amino acid refers to an amino acid selected from the group consisting of Glycine (Gly), Serine (Ser), Threonine (Thr), Cysteine (Cys), Tyrosine (Tyr), Asparagine (Asn), and Glutamine (Gin).
  • the acylated FA-aa includes the amino acid residue of a polar acidic amino acid.
  • the acylated FA-aa may be represented by the general formula A-X, wherein A is the amino acid residue of a polar acidic amino acid and X is a fatty acid attached by acylation to A's alpha-amino group.
  • the term "polar acidic amino acid” as used herein refers to categorisation of amino acids used by the person skilled in the art.
  • the term “polar acidic amino acid” refers to an amino acid selected from the group consisting of Aspartic acid (Asp) and Glutamic acid (Glu).
  • the amino acid residue of the acylated FA-aa includes the amino acid residue of an amino acid that is not encoded by the genetic code. Modifications of amino acids by acylation may be readily performed using acylation agents known in the art that react with the free alpha-amino group of the amino acid.
  • the alpha-amino acids or the alpha-amino acid residues herein are in the L-form unless otherwise stated.
  • the amino acid residue is in the free acid form and/or a salt thereof, such as a sodium (Na+) salt thereof.
  • acylated FA-aas may be represented by the general Fa-aa formula I:
  • R1 is an alkyl or aryl group including 5 to 19 carbon atoms;
  • R2 is
  • R4 is H (i.e. hydrogen), CH 3 (i.e. methyl group), or covalently attached to R4 via a (CH2)3 group; R3 is H or absent; and R4 is an amino acid side chain or covalently attached to R2 via a (CH2)3 group; or a salt thereof.
  • the FA-aa can be acylated with a fatty acid including a substituted or unsubstituted alkyl group consisting of 5 to 19 carbon atoms.
  • the alkyl group consists of 5 to 17 carbon atoms.
  • the alkyl group consists of 5-15 carbon atoms.
  • the alkyl group consists of 5-13 carbon atoms.
  • the alkyl group consists of 6 carbon atoms.
  • the acylated FA-aa is soluble at intestinal pH values, particularly in the range pH 5.5 to 8.0, such as in the range pH 6.5 to 7.0. In particular embodiments, the acylated FA-aa is soluble below pH 9.0.
  • the acylated FA-aa has a solubility of at least 5 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 10 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 20 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 30 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 40 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 50 mg/mL.
  • the acylated FA-aa has a solubility of at least 60 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 70 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 80 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 90 mg/mL. In particular embodiments, the acylated FA-aa has a solubility of at least 100 mg/mL.
  • solubility of the acylated FA-aa is determined in an aqueous solution at a pH value 1 unit above or below pKa of the FA-aa at 37° C. In particular embodiments, solubility of the acylated FA-aa is determined in an aqueous solution at pH 8 at 37°C. In particular embodiments, solubility of the acylated FA-aa is determined in an aqueous solution at a pH value 1 unit above or below pi of the FA-aa at 37° C.
  • solubility of the acylated FA-aa is determined in an aqueous solution at a pH value 1 units above or below pi of the FA-aa at 37° C, wherein said FA-aa two or more ionisable groups with opposite charges.
  • solubility of the FA-aa is determined in an aqueous 50 mM sodium phosphate buffer, pH 8.0 at 37° C.
  • the acylated FA-aa is selected from the group consisting of formula (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (I), (m), (n), (o), (p), (q), and (r), wherein R1 is an alkyl group including 5 to 19 carbon atoms, R2 is H (i.e. hydrogen) or CH3 (i.e. methyl group), and R3 is H; or a salt or the free acid form thereof.
  • Formulas (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (I), (m), (n), (o), (p), (q), and (r) are provided in FIG. 4.
  • the acylated FA-aa can be selected from one or more of sodium /V-dodecanoyl alaninate, /V-dodecanoyl-L-alanine, sodium /V-dodecanoyl isoleucinate, N- dodecanoyl-L-isoleucine, sodium /V-dodecanoyl leucinate, /V-dodecanoyl-L-leucine, sodium N- dodecanoyl methioninate, /V-dodecanoyl-L-methionine, sodium /V-dodecanoyl phenylalaninate, /V-dodecanoyl-L-phenylalanine, sodium /V-dodecanoyl prolinate, /V-dodecanoyl-L-proline, sodium /V-dodecanoyl tryptophanate,
  • fatty acid /V-acylated amino acid refers to an amino acid that is acylated with a fatty acid at its alpha-amino group.
  • Particular embodiments utilize vegetable matter with low solubility, or very low solubility.
  • Particular embodiments utilize vegetable matter that is essentially water insoluble.
  • solubility in water is defined as low to zero by the United States pharmacopeia (USP 32) according to the amount of water necessary for the dissolution of one part of solute: Low solubility: 100 to 1000 parts of water necessary for dissolution of one part of solute; very low solubility: 1000 to 10 000 parts of water necessary; essentially water insoluble more than 10 000 parts of water necessary.
  • SNAC and other modified amino acids and FA- aas described herein are water soluble.
  • very low solubility can refer to a solubility in water or an aqueous solution of less than 1 mg/ml, less than 0.1 mg/ml, or less than 0.01 mg/ml.
  • Absorption enhancing agents refer to compounds that promote gastrointestinal absorption. Absorption enhancing agents can improve drug absorption by improving the solubility of the drug in the gastrointestinal tract or by enhancing membrane penetration, as compared to a formulation that does not include the absorption enhancing agents. Additional examples of absorption enhancing agents include surfactants, detergents, azones, pyrrolidones, glycols or bile salts.
  • bioavailability enhancing agents act as bioavailability enhancing agents.
  • Bioavailability refers to the fraction of active ingredient that is actually absorbed by a subject and reaches the bloodstream.
  • bioavailability enhancing agents increase the fraction of active ingredient in the bloodstream or result in detection of active ingredient in the bloodstream earlier in time, as compared to a formulation that does not include the bioavailability enhancing agent.
  • additional administration benefits created by absorption enhancing agents and/or bioavailability enhancing agents include faster onset of action, higher peak concentrations, faster time to peak concentrations, shorter duration of action, increased subjective therapeutic efficacy, and/or increased objective therapeutic efficacy as compared to a control plant-based composition or oral formulation based on the same, similar in all aspects but for inclusion of the absorption enhancing agents and/or bioavailability enhancing agents.
  • Embodiments utilizing absorption enhancing agents and/or bioavailability enhancing agents can be beneficial because many oral plant-based compositions designed to address various physiological conditions are inadequate because they are characterized by a delayed onset of action, and low bioavailability. Delayed onset of action presents challenges in clinical indications that require rapid therapeutic effect (e.g. pain and migraine); and low bioavailability requires patients to ingest significantly higher doses than would be required by alternative dosing forms (e.g. smoking, vaping). Particular embodiments disclosed herein provide plant-based composition oral formulations with improved bioavailability and shorter time to onset of therapeutic effect.
  • absorption enhancing agents and/or bioavailability enhancing agents e.g., and in particular embodiments, /V-acylated fatty amino acids
  • /V-acylated fatty amino acids act as subjective therapy enhancing agents.
  • Subjective therapy enhancement refers to a noticeable alleviation of a symptom, as perceived by a subject.
  • subjective therapy enhancing agents increase the alleviation of a symptom or alleviate a symptom more quickly, as compared to a formulation that does not include the subjective therapy enhancing agent.
  • /V-acylated fatty amino acids act as objective therapy enhancing agents.
  • Objective therapy enhancement refers to alleviation of a clinical measure, such as a nutritional deficiency detected by a blood or saliva assay or a test of wellness, as administered by a physician.
  • objective therapy enhancing agents increase the alleviation of an objective clinical measure or result in alleviation more quickly, as compared to a formulation that does not include the objective therapy enhancing agent.
  • Particular embodiments include cannabis and an absorption enhancing agent and/or bioavailability enhancing agent. These embodiments can allow more rapid cannabis absorption and higher bioavailability compared to cannabis ingested by currently available oral dosage forms.
  • carriers disclosed herein create administration benefits selected from: increased absorption, increased bioavailability, faster onset of action, higher peak concentrations, faster time to peak concentrations, shorter duration of action, increased subjective therapeutic efficacy, increased objective therapeutic efficacy, improved taste, and improved mouthfeel.
  • Administration benefits related to increased absorption, increased bioavailability, faster onset of action, higher peak concentrations, faster time to peak concentrations, shorter duration of action can alleviate adverse conditions more rapidly (for example, alleviation of pain).
  • “Mouthfeel” refers to non-taste-reiated aspects of the pleasantness experienced by a person while ingesting (e.g., chewing or swallowing) an oral dosage form. Aspects of mouthfeel include the hardness and brittieness of a composition, whether the composition is chewy, gritty, oily, creamy, watery, sticky, easily dissolved, astringent, effervescent, and the like, and the size, shape, and form of the composition (tablet, powder, gel, etc.).
  • Plant-based compositions can be manufactured for administration to a subject by adding vegetable matter, a carrier that provides an administration benefit, and one or more excipients, mixing, suspending, dissolving, blending, granulating, tableting, encapsulating, or performing other dosage-form-specific procedures, followed by packaging.
  • carriers contribute to providing an administration benefit.
  • Excipients can, but need not, contribute to an administration benefit.
  • compositions prepared as oral formulations include capsules, coated tablets, edibles, elixirs, emulsions, gels, gelcaps, granules, gums, juices, liquids, oils, pastes, pellets, pills, powders, rapidly-dissolving tablets, sachets, semi-solids, sprays, solutions, suspensions, syrups, tablets, etc.
  • excipient classes include binders, buffers, chelators, coating agents, colorants, complexation agents, diluents (i.e., fillers), disintegrants, emulsifiers, flavoring agents, glidants, lubricants, preservatives, releasing agents, surfactants, stabilizing agents, solubilizing agents, sweeteners, thickening agents, wetting agents, and vehicles.
  • Binders are substances used to cause adhesion of powder particles in granulations.
  • exemplary binders include acacia, compressible sugar, gelatin, sucrose and its derivatives, maltodextrin, cellulosic polymers, such as ethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose, carboxymethylcellulose sodium and methylcellulose, acrylic polymers, such as insoluble acrylate ammoniomethacrylate copolymer, polyacrylate or polymethacrylic copolymer, povidones, copovidones, polyvinylalcohols, alginic acid, sodium alginate, starch, pregelatinized starch, guar gum, and polyethylene glycol.
  • [008S]Colorants may be included in the oral formulations to impart color to the formulation.
  • Exemplary colorants include grape skin extract, beet red powder, beta carotene, annato, carmine, turmeric, and paprika. Additional colorants include FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, FD&C Orange No. 5, D&C Red No. 8, caramel, and ferric oxide.
  • Diluents can enhance the granulation of oral formulations.
  • exemplary diluents include microcrystalline cellulose, sucrose, dicalcium phosphate, starches, lactose and polyols of less than 13 carbon atoms, such as mannitol, xylitol, sorbitol, maltitol and pharmaceutically acceptable amino acids, such as glycin.
  • Disintegrants also may be included in the oral formulations in order to facilitate dissolution.
  • Disentegrants including permeabilising and wicking agents, are capable of drawing water or saliva up into the oral formulations which promotes dissolution from the inside as well as the outside of the oral formulations.
  • Such disintegrants, permeabilising and/or wicking agents include starches, such as corn starch, potato starch, pre-gelatinized and modified starches thereof, cellulosic agents, such as Ac-di-sol, montmorrilonite clays, cross-linked PVP, sweeteners, bentonite, microcrystalline cellulose, croscarmellose sodium, alginates, sodium starch glycolate, gums, such as agar, guar, locust bean, karaya, pectin, Arabic, xanthan and tragacanth, silica with a high affinity for aqueous solvents, such as colloidal silica, precipitated silica, maltodextrins, beta-cyclodextrins, polymers, such as carbopol, and cellulosic agents, such as hydroxymethylcellulose, hydroxypropylcellulose and hydroxyopropylmethylcellulose. Dissolution of the oral formulations may be facilitated by including relatively small particles sizes of the oral formulations
  • Exemplary dispersing or suspending agents include acacia, alginate, dextran, fragacanth, gelatin, hydrogenated edible fats, methylcellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, sorbitol syrup, and synthetic natural gums.
  • Exemplary emulsifiers include acacia and lecithin.
  • flavorants are natural or artificial compounds used to impart a pleasant flavor and often odor to oral formulations.
  • Exemplary flavorants include, natural and synthetic flavor oils, flavoring aromatics, extracts from plants, leaves, flowers, and fruits and combinations thereof.
  • Such flavorants include anise oil, cinnamon oil, vanilla, vanillin, cocoa, chocolate, natural chocolate flavor, menthol, grape, peppermint oil, oil of wintergreen, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oil of bitter almonds, cassia oil; citrus oils, such as lemon, orange, lime and grapefruit oils; and fruit essences, including apple, pear, peach, berry, wildberry, date, blueberry, kiwi, strawberry, raspberry, cherry, plum, pineapple, and apricot.
  • flavorants that may be used include natural berry extracts and natural mixed berry flavor, as well as citric and malic acid.
  • glidants improve the flow of powder blends during manufacturing and minimize oral formulation weight variation.
  • exemplary glidants include silicon dioxide, colloidal or fumed silica, magnesium stearate, calcium stearate, stearic acid, cornstarch, and talc.
  • Lubricants are substances used in oral formulations that reduce friction during composition compression.
  • Exemplary lubricants include stearic acid, calcium stearate, magnesium stearate, zinc stearate, talc, mineral and vegetable oils, benzoic acid, poly(ethylene glycol), glyceryl behenate, stearyl fumarate, and sodium lauryl sulfate.
  • Exemplary preservatives include methyl p-hydroxybenzoates, propyl p-hydroxybenzoates, and sorbic acid.
  • Exemplary sweeteners include aspartame, dextrose, fructose, high fructose corn syrup, maltodextrin, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, potassium acesulfame, saccharin sodium, stevia, sucralose, and sucrose.
  • swallowable compositions include swallowable compositions.
  • Swallowable compositions are those that do not readily dissolve when placed in the mouth and may be swallowed whole without chewing or discomfort.
  • U.S. Pat. Nos. 5,215,754 and 4,374,082 describe methods for preparing swallowable compositions.
  • swallowable compositions may have a shape containing no sharp edges and a smooth, uniform and substantially bubble free outer coating.
  • each of the ingredients may be combined in intimate admixture with a suitable carrier according to conventional compounding techniques.
  • the surface of the compositions may be coated with a polymeric film.
  • Such a film coating has several beneficial effects. First, it reduces the adhesion of the compositions to the inner surface of the mouth, thereby increasing the subject's ability to swallow the compositions. Second, the film may aid in masking the unpleasant taste of certain ingredients. Third, the film coating may protect the compositions from atmospheric degradation.
  • Polymeric films that may be used in preparing the swallowable compositions include vinyl polymers such as polyvinylpyrrolidone, polyvinyl alcohol and acetate, cellulosics such as methyl and ethyl cellulose, hydroxyethyl cellulose and hydroxylpropyl methylcellulose, acrylates and methacrylates, copolymers such as the vinyl-maleic acid and styrene-maleic acid types, and natural gums and resins such as zein, gelatin, shellac and acacia.
  • vinyl polymers such as polyvinylpyrrolidone, polyvinyl alcohol and acetate
  • cellulosics such as methyl and ethyl cellulose, hydroxyethyl cellulose and hydroxylpropyl methylcellulose
  • acrylates and methacrylates copolymers
  • copolymers such as the vinyl-maleic acid and styrene-maleic acid types
  • natural gums and resins such as
  • the oral formulations may include chewable compositions.
  • Chewable compositions are those that have a palatable taste and mouthfeel, are relatively soft and quickly break into smaller pieces and begin to dissolve after chewing such that they are swallowed substantially as a solution.
  • U.S. Pat. No. 6,495, 177 describes methods to prepare chewable compositions with improved mouthfeel.
  • U.S. Pat. No. 5,965, 162 describes kits and methods for preparing comestible units which disintegrate quickly in the mouth, especially when chewed.
  • chewable compositions should include ingredients that create pleasant flavor and mouthfeel and promote relative softness and dissolvability in the mouth.
  • ingredients that may help to achieve these characteristics.
  • [QlOOJSugars such as white sugar, corn syrup, sorbitol (solution), maltitol (syrup), oligosaccharide, isomaltooligosaccharide, sucrose, fructose, lactose, glucose, lycasin, xylitol, lactitol, erythritol, mannitol, isomaltose, dextrose, polydextrose, dextrin, compressible cellulose, compressible honey, compressible molasses and mixtures thereof may be added to improve mouthfeel and palatability.
  • oligosaccharide such as white sugar, corn syrup, sorbitol (solution), maltitol (syrup), oligosaccharide, isomaltooligosaccharide, sucrose, fructose, lactose, glucose, lycasin, xylitol, lactitol, erythritol, mannito
  • Fondant or gums such as gelatin, agar, arabic gum, guar gum, and carrageenan may be added to improve the chewiness of the compositions.
  • Fatty materials that may be used include vegetable oils (including palm oil, palm hydrogenated oil, corn germ hydrogenated oil, castor hydrogenated oil, cotton-seed oil, olive oil, peanut oil, palm olein oil, and palm stearin oil), animal oils (including refined oil and refined lard whose melting point ranges from 30° to 42° C), Cacao fat, margarine, butter, and shortening.
  • Alkyl polysiloxanes also may be used to enhance the texture, the mouthfeel, or both of chewable compositions.
  • “enhance the texture” it is meant that the alkyl polysiloxane improves one or more of the stiffness, the brittleness, and the chewiness of the chewable composition, relative to the same preparation lacking the alkyl polysiloxane.
  • “enhance the mouthfeel” it is meant that the alkyl polysiloxane reduces the gritty texture of the chewable composition once it has liquefied in the mouth, relative to the same preparation lacking the alkyl polysiloxane.
  • Alkyl polysiloxanes generally include a silicon and oxygen-containing polymeric backbone with one or more alkyl groups pending from the silicon atoms of the back bone. Depending upon their grade, they can further include silica gel. Alkyl polysiloxanes are generally viscous oils. Exemplary alkyl polysiloxanes that can be used in swallowable, chewable or dissolvable compositions include monoalkyl or dialkyl polysiloxanes, wherein the alkyl group is independently selected at each occurrence from a Ci-C6-alkyl group optionally substituted with a phenyl group.
  • simethicone dimethyl polysiloxane
  • simethicone GS a granular simethicone preparation designated simethicone GS may be used.
  • Simethicone GS is a preparation which contains 30% simethicone USP.
  • Simethicone USP contains not less than 90.5% by weight (CH3)3-Si ⁇ OSi(CH3)2 ⁇ CH3 in admixture with 4.0% to 7.0% by weight Si0 2 .
  • the compositions may further include emulsifiers such as glycerin fatty acid ester, sorbitan monostearate, sucrose fatty acid ester, lecithin and mixtures thereof.
  • emulsifiers such as glycerin fatty acid ester, sorbitan monostearate, sucrose fatty acid ester, lecithin and mixtures thereof.
  • one or more of such emulsifiers may be present in an amount of 0.01 % to 5.0%, by weight of the administered formulations. If the level of emulsifier is lower or higher, in particular embodiments, an emulsification cannot be realized, or wax value will rise.
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for reconstitution with water or other suitable vehicles before use.
  • any appropriate fillers and excipients may be utilized in preparing the swallowable, chewable and/or dissolvable compositions or any other oral formulation described herein so long as they are consistent with the described objectives.
  • Oral formulations also include edibles.
  • Edibles refer to any product that can be consumed as a food or a drink. In some cases, edibles are made by infusion of plant extracts into a foodstuff. Examples of edible foods appropriate for use include candy, a candy bar, bread, a brownie, cake, cheese, chocolate, cocoa, a cookie, gummy candy, a lollipop, a mint, a pastry, peanut butter, popcorn, a protein bar, rice cakes, yogurt, etc. While technically not edible, gums can also be used. Examples of edible drinks include beer, juice, flavored milk, flavored water, liquor, milk, punch, a shake, soda, tea, and water.
  • edibles are made by combining a plant extract with ingredients used to make an edible.
  • examples include butters and oils.
  • oils include coconut oil, grape seed oil, olive oil, palm oil, papaya seed oil, peanut oil, sesame oil, sprouted wheat oil, wheat germ oil, or any combination thereof.
  • Oral formulations can be individually wrapped or packaged as multiple units in one or more packages, cans, vials, blister packs, or bottles of any size. Doses are sized to provide therapeutically effective amounts.
  • the oral formulations include vegetable matter (e.g., plant parts or extracts) of at least 0.1 % w/v or w/w of the oral formulation; at least 1 % w/v or w/w of oral formulation; at least 10% w/v or w/w of oral formulation; at least 20% w/v or w/w of oral formulation; at least 30% w/v or w/w of oral formulation; at least 40% w/v or w/w of oral formulation; at least 50% w/v or w/w of oral formulation; at least 60% w/v or w/w of oral formulation; at least 70% w/v or w/w of oral formulation; at least 80% w/v or w/w of oral formulation; at least 90% w/v or w/w of oral formulation; at least 95% w/v or w/w of oral formulation; or at least 99% w/v or w/w of oral formulation.
  • vegetable matter e.g., plant parts or extracts
  • the oral formulations include carrier of at least 0.1 % w/v or w/w of the oral formulation; at least 1 % w/v or w/w of oral formulation; at least 10% w/v or w/w of oral formulation; at least 20% w/v or w/w of oral formulation; at least 30% w/v or w/w of oral formulation; at least 40% w/v or w/w of oral formulation; at least 50% w/v or w/w of oral formulation; at least 60% w/v or w/w of oral formulation; at least 70% w/v or w/w of oral formulation; at least 80% w/v or w/w of oral formulation; at least 90% w/v or w/w of oral formulation; at least 95% w/v or w/w of oral formulation; or at least 99% w/v or w/w of oral formulation.
  • the oral formulations include excipient of at least 0.1 % w/v or w/w of the oral formulation; at least 1 % w/v or w/w of oral formulation; at least 10% w/v or w/w of oral formulation; at least 20% w/v or w/w of oral formulation; at least 30% w/v or w/w of oral formulation; at least 40% w/v or w/w of oral formulation; at least 50% w/v or w/w of oral formulation; at least 60% w/v or w/w of oral formulation; at least 70% w/v or w/w of oral formulation; at least 80% w/v or w/w of oral formulation; at least 90% w/v or w/w of oral formulation; at least 95% w/v or w/w of oral formulation; or at least 99% w/v or w/w of oral formulation.
  • 10 g of dried plant extract may be used in 150 ml of water. This may give an effective concentration of between 1 and 99% (w/w) plant extract, between 2 and 80% (w/w) plant extract, and between 5 and 50% (w/w) plant extract.
  • Plant-based compositions disclosed herein can be used to treat subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.), livestock (horses, cattle, goats, pigs, chickens, etc.), and research animals (monkeys, rats, mice, fish, etc.)). Treating subjects includes providing therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments, and/or therapeutic treatments. [0115]An "effective amount" is the amount of a plant-based composition necessary to result in a desired physiological change in a subject. Effective amounts are often administered for research purposes.
  • Representative effective amounts disclosed herein can reduce pain perception in an animal model (neuropathic pain, acute pain, visceral pain), stimulate appetite in an animal model, reduce seizures (e.g., epileptic seizures) in an animal model, reverse bone loss in an animal model, relieve migraine (vasoconstrict cranial blood vessels) in an animal model, treat addiction in an animal model, reduce anxiety in an animal model, and/or reduce symptoms of asthma in an animal model.
  • seizures e.g., epileptic seizures
  • migraine vasoconstrict cranial blood vessels
  • a prophylactic treatment includes a treatment administered to a subject who does not display signs or symptoms of a disease or nutritional deficiency, or displays only early signs or symptoms of a disease or nutritional deficiency, such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing the disease or nutritional deficiency further.
  • a prophylactic treatment functions as a preventative treatment against the development of diseases or nutritional deficiencies.
  • an oral formulation disclosed herein can be administered to a subject who is at risk of developing a migraine headache.
  • An effective prophylactic treatment of a migraine headache occurs when the number of migraines per month experienced by a subject is reduced by at least 10% or in particular embodiments, by 25%.
  • an oral formulation disclosed herein can be administered to a subject who is at risk of having an epileptic seizure.
  • An effective prophylactic treatment of epileptic seizures occurs when the number of seizures per month is reduced by at least 10% or in particular embodiments, by 25%.
  • an oral formulation disclosed herein can be administered to a subject who is at risk of suffering from neuropathic pain.
  • An effective prophylactic treatment of neuropathic pain occurs when the occurrence of the neuropathic pain is reduced by at least 10%, or in particular embodiments, by 25% as measured by a standard subjective or objective pain assessment.
  • an oral formulation disclosed herein can be administered to a subject who is at risk of developing breakthrough pain.
  • An effective prophylactic treatment of breakthrough pain occurs when the occurrence of breakthrough pain is reduced by 10%, and in particular embodiments, by 25% by a standard subjective or objective pain assessment.
  • an oral formulation disclosed herein can be administered to a subject who is at risk of developing chemotherapy induced nausea and vomiting (CINV).
  • CINV chemotherapy induced nausea and vomiting
  • An effective prophylactic treatment of CINV occurs when CINV is reduced by 10%, and in particular embodiments, by 25% measured by a standard subjective or objective CINV assessment.
  • an oral formulation disclosed herein can be administered to a subject who is at risk of developing rickets from insufficient vitamin C, anemia from insufficient dietary iron, and/or bone loss from insufficient calcium.
  • An effective prophylactic treatment of these conditions occurs when the conditions are avoided or delayed due to nutritional supplementation with an oral formulation disclosed herein.
  • a "therapeutic treatment” includes a treatment administered to a subject who has a disease or nutritional deficiency and is administered to the subject for the purpose of curing or reducing the severity of the disease or nutritional deficiency.
  • an oral formulation disclosed herein can be administered to a subject who has a migraine headache.
  • An effective therapeutic treatment of the migraine headache occurs when the severity of the headache is reduced or relieved completely and/or the headache resolves more quickly measured by a standard subjective or objective headache assessment.
  • a therapeutic treatment of CINV includes administration of an oral formulation disclosed herein to a subject experiencing CINV.
  • a therapeutic treatment of CINV occurs when the vomiting is reduced or ceases (or ceases more quickly) and the nausea is relieved measured by a standard subjective or objective CINV assessment.
  • An effective therapeutic treatment of osteoporosis occurs when bone density has increased by 10% and in particular embodiments, by 25%.
  • Another example of a therapeutic treatment includes administration of an oral formulation disclosed herein to a subject who has anxiety.
  • An effective therapeutic treatment of anxiety occurs when the severity of the anxiety is reduced or relieved completely and/or more quickly measured by a standard subjective or objective anxiety assessment.
  • Another example of a therapeutic treatment includes administration of an oral formulation disclosed herein to a subject who has multiple sclerosis.
  • An effective therapeutic treatment of multiple sclerosis occurs when the score in a standard walk test improves by 10% and in particular embodiments, by 25%.
  • an oral formulation disclosed herein can be administered to a subject who has rickets from insufficient vitamin C, anemia from insufficient dietary iron, and/or bone loss from insufficient calcium.
  • An effective therapeutic treatment of these conditions occurs when the conditions are reduced or resolved due to nutritional supplementation with an oral formulation disclosed herein.
  • Therapeutic treatments can be distinguished from effective amounts based on the presence or absence of a research component to the administration. As will be understood by one of ordinary skill in the art, however, in human clinical trials effective amounts, prophylactic treatments and therapeutic treatments can overlap.
  • therapeutically effective amounts can be initially estimated based on results from in vitro assays and/or animal model studies. Such information can be used to more accurately determine useful doses in subjects of interest.
  • the actual dose amount administered to a particular subject can be determined by the subject, a physician, veterinarian, or researcher taking into account parameters such as physical, physiological and psychological factors including target, body weight, condition, previous or concurrent therapeutic interventions, and/or idiopathy of the subject.
  • a dose can range from 0.1 to 5 ⁇ g/kg or from 0.5 to 1 ⁇ g /kg.
  • a dose can include 1 ⁇ g /kg, 5 ⁇ g /kg, 10 ⁇ g /kg, 15 ⁇ g /kg, 20 ⁇ g /kg, 25 ⁇ g /kg, 30 ⁇ g /kg, 35 ⁇ g/kg, 40 ⁇ g/kg, 45 ⁇ g/kg, 50 ⁇ g/kg, 55 ⁇ g/kg, 60 ⁇ g/kg, 65 ⁇ g/kg, 70 ⁇ g/kg, 75 ⁇ g/kg, 80 ⁇ g/kg, 85 ⁇ g/kg, 90 ⁇ g/kg, 95 ⁇ g/kg, 100 ⁇ g/kg, 150 ⁇ g/kg, 200 ⁇ g/kg, 250 ⁇ g/kg, 350 ⁇ g/kg, 400 ⁇ g/kg, 450 ⁇ g/kg, 500 ⁇ g/kg, 550 ⁇
  • a dose can include 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90 mg/kg, 95 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, 1000 mg/kg or more.
  • Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., hourly, every 2 hours, every 3 hours, every 4 hours, every 6 hours, every 9 hours, every 12 hours, every 18 hours, daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, or monthly).
  • a treatment regimen e.g., hourly, every 2 hours, every 3 hours, every 4 hours, every 6 hours, every 9 hours, every 12 hours, every 18 hours, daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, or monthly.
  • One or more active agent(s) can be administered simultaneously or within a selected time window, such as within 10 minutes, 1 hour, 3 hour, 10 hour, 15 hour, 24 hour, or 48 hour time windows or when the complementary active agent(s) is within a clinically-relevant therapeutic window.
  • a selected time window such as within 10 minutes, 1 hour, 3 hour, 10 hour, 15 hour, 24 hour, or 48 hour time windows or when the complementary active agent(s) is within a clinically-relevant therapeutic window.
  • a plant-based composition including vegetable matter and an /V-acylated fatty amino acid or a salt thereof.
  • a plant-based composition of embodiment 1 including a botanical product.
  • a plant-based composition of any of embodiments 1-7 including A9-Tetrahydrocannabinol (THC) and cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof.
  • a plant-based composition of any of embodiments 1-11 wherein the /V-acylated fatty amino acid or a salt thereof includes
  • X and Z are independently H, a monovalent cation, a divalent metal cation, or an organic cation.
  • a plant-based composition of embodiment 26 wherein the administration benefit is a dose-dependent administration benefit.
  • a plant-based composition of embodiment 27 wherein the dose-dependent administration benefit is at a dose of 100-200mg.
  • An plant-based composition of embodiment 26 wherein the administration benefit includes one or more of increased absorption of a measured component of vegetable matter, increased bioavailability of a measured component of vegetable matter, faster onset of action of a measured component of vegetable matter, higher peak concentrations of a measured component of vegetable matter, faster time to peak concentrations of a measured component of vegetable matter, shorter duration of action, increased subjective therapeutic efficacy, increased objective therapeutic efficacy, improved taste, and improved mouthfeel as compared to a control composition without the /V-acylated fatty amino acid.
  • a plant-based composition of any of embodiments 1-31 including a surfactant, detergent, azone, pyrrolidone, glycol or bile salt.
  • a plant-based composition of any of embodiments 1-32 including a therapeutically effective amount of vegetable matter including a therapeutically effective amount of vegetable matter.
  • a plant-based composition of embodiment 33 wherein the therapeutically effective amount treats a symptom of acquired hypothyroidism, acute gastritis, addiction, ADHD, agoraphobia, AIDS, AIDS-related anorexia, alcoholism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ankyloses, anxiety, arthritis, Asperger's syndrome, asthma, atherosclerosis, autism, auto-immune diseases, bacterial infections, bipolar disorder, bone loss, blood disorders, brain injury/stroke, cachexia, cancer, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy, fever, fibromyalgia, flu, fungal infection, gastrointestinal disorders, glaucoma, glioma, Grave's disease, heart disease
  • An oral formulation including a plant-based composition of any of embodiments 1-38.
  • An oral formulation of embodiment 39 wherein the oral formulation is swallowable or chewable.
  • a method of preparing an oral formulation of cannabis having a faster onset of action wherein the method comprises adding an absorption enhancer to the oral formulation of cannabis and wherein the oral formulation of cannabis has a faster onset of action than an oral formulation of cannabis without an absorption enhancer.
  • X and Z are independently H, a monovalent cation, a divalent metal cation, or an organic cation.
  • N-acylated fatty amino acid is selected from monosodium-/V-salicyloyl-8-aminocaprylate, disodium-/V-salicyloyl-8- aminocaprylate, and A/-(salicyloyl)-8- aminocaprylic acid.
  • a method of treating a subject in need thereof including administering a therapeutically effective amount of a composition of any of embodiments 1-39 or a formulation of any of embodiments 40-45 to the subject thereby treating the subject in need thereof.
  • a method of embodiment 50 wherein the therapeutically effective amount provides an effective amount, a prophylactic treatment, and/or a therapeutic treatment.
  • a method of reducing or eliminating one or more symptoms of a disease or disorder in a human subject
  • said method includes delivering a therapeutically effective amount of a composition of any of embodiments 1-39 or oral formulation of any of embodiments 40-45 to the subject, thereby reducing or eliminating one or more symptoms of the disease or disorder, and wherein said disease or disorder is acquired hypothyroidism, acute gastritis, addiction, ADHD, agoraphobia, AIDS, AIDS-related anorexia, alcoholism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ankyloses, anxiety, arthritis, Asperger's syndrome, asthma, atherosclerosis, autism, auto-immune diseases, bacterial infections, bipolar disorder, bone loss, blood disorders, brain injury/stroke, cachexia, cancer, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy,
  • Oral cannabinoid dosage form providing improved bioavailability and shortened time to onset of effect.
  • Current oral cannabis products include edibles and traditional pharmaceutical dosage forms that are challenged by low bioavailability, and prolonged time to onset of action.
  • the present disclosure addresses the shortcomings of all of the currently available oral cannabis products to provide an improved time to onset of effect and improved bioavailability.
  • Example 1 Exemplary Formulations. Solution formulation. Cannabis and one or more N- acylated fatty amino acids are combined in an aqueous/organic solvent mixture. The resulting blend is stirred vigorously for an hour. If solution is incomplete, a surfactant can be added and stirring can be continued to prepare the final formulation.
  • Cannabis and one or more /V-acylated fatty amino acids are combined in water, an aqueous/organic solvent mixture or an organic solvent mixture.
  • the resulting blend can be stirred to effect suspension.
  • Solution formulation Cannabis and one or more absorption enhancing agents are combined in an aqueous/organic solvent mixture. The resulting blend is stirred vigorously for an hour. If solution is incomplete, a surfactant can be added and stirring can be continued to prepare the final formulation.
  • Cannabis and one or more absorption enhancing agents are combined in water, an aqueous/organic solvent mixture or an organic solvent mixture.
  • the resulting blend can be stirred to effect suspension.
  • [G142JGelcap composition A suspension formulation or solution formulation can be filled into a gelcap to contain up to 1 g of cannabis.
  • the gelcap can be treated with an enteric coat or used without a coating.
  • the solution formulation and the suspension formulation can be dried by evaporation, lyophilization, or spray drying.
  • the resultant dry product can be combined with tableting excipients and compressed into tablets or caplets to contain up to 1 g of cannabis. Alternatively, the dry product can be filled into capsules.
  • Example 2 Onset and duration of action of orally administered cannabis/SNAC composition. This study was designed to assess the utility of SNAC in enabling a rapid-acting oral form of cannabis.
  • the selected cannabis concentrate is commercially available and was provided to participants in an ethanol solution.
  • the concentrate contains 8 mg THC per dose. It was selected because it contains a high percentage of THC, which provides a noticeable effect on user-reported "euphoria”.
  • Aqueous ethanol was used as solvent because it effectively dissolves cannabis extract, as well as SNAC.
  • each participant mixed the cannabis concentrate with a pre-mixed solution of aqueous ethanol and 200mg SNAC, and immediately swallowed the dissolved mixture.
  • each participant recorded the time of dose administration, the time of onset of euphoria and/or dysphoria, and the observed level of euphoria and/or dysphoria in fifteen minute intervals for five hours following administration of the cannabis dose.
  • Euphoria and dysphoria were reported using a scale value, in a range from 1-10. Table 1 shows descriptions of euphoria and dysphoria levels for each scale value.
  • Results are the average scale values obtained for all six participants (also shown in FIGs. 5A and 5B).
  • the selected cannabis concentrate is commercially available and was provided to participants in an ethanol solution.
  • the concentrate contains 8 mg THC per dose. It was selected because it contains a high percentage of THC, which provides a noticeable effect on user-reported "euphoria”.
  • Aqueous ethanol was used as solvent because it effectively dissolves cannabis extract, as well as SNAC.
  • each participant mixed the cannabis concentrate with a pre-mixed solution of aqueous ethanol and 100mg SNAC, and immediately swallowed the dissolved mixture.
  • each participant recorded the time of dose administration, the time of onset of euphoria and/or dysphoria, and the observed level of euphoria and/or dysphoria in fifteen minute intervals for five hours following administration of the cannabis dose.
  • Euphoria and dysphoria were reported using a scale value, in a range from 1-5.
  • Table 1 shows descriptions of euphoria and dysphoria levels for each scale value.
  • adding an absorption enhancer such as SNAC
  • an absorption enhancer such as SNAC
  • adding an absorption enhancer provides faster onset of action and higher intensity of action at peak activity level of cannabis.
  • the absorption enhancer has no effect on the duration of action of cannabis.
  • the varying quantity of SNAC produces a clear dose-response relationship between observed cannabis effect (euphoria) and SNAC dose.
  • each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component.
  • the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.”
  • the transition term “comprise” or “comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts.
  • the transition phrase “consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment.
  • a material effect would cause a statistically-significant reduction in an administration benefit when assessed in an experimental protocol disclosed herein.
  • the term "about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ⁇ 20% of the stated value; ⁇ 19% of the stated value; ⁇ 18% of the stated value; ⁇ 17% of the stated value; ⁇ 16% of the stated value; ⁇ 15% of the stated value; ⁇ 14% of the stated value; ⁇ 13% of the stated value; ⁇ 12% of the stated value; ⁇ 1 1 % of the stated value; ⁇ 10% of the stated value; ⁇ 9% of the stated value; ⁇ 8% of the stated value; ⁇ 7% of the stated value; ⁇ 6% of the stated value; ⁇ 5% of the stated value; ⁇ 4% of the stated value; ⁇ 3% of the stated value; ⁇ 2% of the stated value; or ⁇ 1 % of the stated value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
PCT/US2017/028953 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements Ceased WO2017185038A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
MX2018012913A MX382853B (es) 2016-04-22 2017-04-21 Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción.
EP17786760.3A EP3445356B1 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
CA3021660A CA3021660A1 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A EA201892396A1 (ru) 2016-12-02 2017-04-21 Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR1020187033084A KR102393596B1 (ko) 2016-04-22 2017-04-21 속효성 식물-계 의약 화합물 및 영양 보충제
AU2017252575A AU2017252575B2 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
BR112018071518-2A BR112018071518A2 (pt) 2016-04-22 2017-04-21 compostos medicinais à base de planta de ação rápida e suplementos nutricionais
US16/094,802 US10588974B2 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
CN201780024997.6A CN109069475B (zh) 2016-04-22 2017-04-21 快速作用植物类医药化合物和营养补剂
EP21175803.2A EP3928776B1 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
JP2019506612A JP6983868B2 (ja) 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤
IL262505A IL262505B (en) 2016-04-22 2018-10-22 Fast-acting plant-based medicinal compounds and nutritional supplements
CONC2018/0011299A CO2018011299A2 (es) 2016-04-22 2018-10-22 Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
US16/805,356 US11129897B2 (en) 2016-04-22 2020-02-28 Fast-acting plant-based medicinal compounds and nutritional supplements
US17/409,417 US20230075677A1 (en) 2016-04-22 2021-08-23 Fast-acting plant-based medicinal compounds and nutritional supplements
JP2021189167A JP7284241B2 (ja) 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤
IL290084A IL290084A (en) 2016-04-22 2022-01-24 Fast-acting plant-based medicinal compounds and nutritional supplements
AU2022201021A AU2022201021B2 (en) 2016-04-22 2022-02-16 Fast-acting plant-based medicinal compounds and nutritional supplements
US18/461,125 US20240261408A1 (en) 2016-04-22 2023-09-05 Fast-acting plant-based medicinal compounds and nutritional supplements
AU2024200704A AU2024200704A1 (en) 2016-04-22 2024-02-06 Fast-acting plant-based medicinal compounds and nutritional supplements
US19/299,150 US20250367295A1 (en) 2016-04-22 2025-08-13 Fast-acting plant-based medicinal compounds and nutritional supplements

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662326490P 2016-04-22 2016-04-22
US62/326,490 2016-04-22
US201662429544P 2016-12-02 2016-12-02
US62/429,544 2016-12-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/094,802 A-371-Of-International US10588974B2 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
US16/805,356 Continuation US11129897B2 (en) 2016-04-22 2020-02-28 Fast-acting plant-based medicinal compounds and nutritional supplements

Publications (1)

Publication Number Publication Date
WO2017185038A1 true WO2017185038A1 (en) 2017-10-26

Family

ID=60117058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/028953 Ceased WO2017185038A1 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements

Country Status (13)

Country Link
US (5) US10588974B2 (https=)
EP (2) EP3928776B1 (https=)
JP (4) JP6983868B2 (https=)
KR (1) KR102393596B1 (https=)
CN (1) CN109069475B (https=)
AU (3) AU2017252575B2 (https=)
BR (1) BR112018071518A2 (https=)
CA (1) CA3021660A1 (https=)
CL (1) CL2018002997A1 (https=)
CO (1) CO2018011299A2 (https=)
IL (2) IL262505B (https=)
MX (2) MX382853B (https=)
WO (1) WO2017185038A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129097A1 (en) * 2017-01-03 2018-07-12 Receptor Life Sciences Medicinal compounds and nutritional supplements
CN110382007A (zh) * 2017-03-23 2019-10-25 受体控股公司 具有恢复的环境效应的组合物的快速和受控递送
WO2020106767A1 (en) * 2018-11-19 2020-05-28 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
WO2020146478A1 (en) * 2019-01-08 2020-07-16 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
WO2020163866A1 (en) * 2019-02-08 2020-08-13 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
WO2021038029A1 (en) 2019-08-30 2021-03-04 Sakso Loaded granules, their process of production and their uses
US11246852B2 (en) 2016-12-02 2022-02-15 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
WO2023091173A1 (en) * 2021-11-16 2023-05-25 Michael Hudnall Methods of liver disease treatment
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
US12252503B2 (en) 2019-07-12 2025-03-18 Canopy Growth Corporation Cannabinoid derivatives
US12410123B2 (en) 2020-05-29 2025-09-09 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3928776B1 (en) 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US20190321330A1 (en) * 2018-04-18 2019-10-24 Canopy Growth Corporation Cannabis placebo compositions, delivery vehicles and a method for colour matching/neutralization of cannabis products
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
JP2022539400A (ja) * 2019-07-04 2022-09-08 キャノピー グロウス コーポレイション カンナビノイド誘導体
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
CN112661663B (zh) * 2020-05-29 2021-09-17 杭州先为达生物科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230047027A1 (en) * 2021-07-13 2023-02-16 Demetrix, Inc. Compositions and methods using cannabinoid compounds for regulating gastric acid secretion to treat gastroesophageal reflux disease and related conditions
CN114539091B (zh) * 2022-03-11 2024-11-05 佛山奕安赛医药科技有限公司 异棕榈酰氨基酸类化合物及其制备方法和应用
CN116474049A (zh) * 2023-03-17 2023-07-25 深圳福图仁泰生物科技有限公司 一种兼具抗抑郁和促睡眠功效的植物天然水溶性复合物及其制备方法和应用
WO2025054536A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Cannabinoid delivery

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194676A1 (en) * 2001-11-29 2008-08-14 Richat Abbas Formulations for oral administration of cromolyn sodium
US20110092583A1 (en) 2005-11-07 2011-04-21 Murty Pharmaceuticals, Inc. Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery
US20120237570A1 (en) * 2009-12-22 2012-09-20 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20140193345A1 (en) 2001-05-23 2014-07-10 Izun Pharmaceuticals Corporation Herbal compositions for the treatment of mucosal lesions
US20140209109A1 (en) * 2013-01-30 2014-07-31 Raymond Louis Larson Smokeless THC and Administration Method Thereof
US20150050373A1 (en) 2012-03-13 2015-02-19 Piramal Enterprises Limited Herbal composition for the treatment of metabolic disorders
US20150057341A1 (en) * 2013-08-22 2015-02-26 Stephen C. Perry Composition with Pharmacological Effect for Vaporizing and Method
US20150126595A1 (en) * 2014-12-04 2015-05-07 Mary's Medicinals LLC Transdermal cannabinoid formulations
US20150181925A1 (en) * 2013-12-26 2015-07-02 John Turner Herbal smoking blend
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385365A (en) 1943-02-17 1945-09-25 Wisconsin Alumni Res Found Salicylic acid compounds for safer therapeutic use
US3939259A (en) 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
DE2537232B2 (de) 1974-08-22 1976-07-01 Spritz- und formmasse
US4374082A (en) 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
EP0273209B1 (en) 1986-12-30 1992-01-15 American Cyanamid Company Composition of matter containing polycarbophil
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4902513A (en) 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US5965162A (en) 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1049474A4 (en) 1998-11-24 2004-12-29 Univ Connecticut CANNABIMIMETIC LIPID AMIDES FOR USE AS MEDICINES
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
CN100391438C (zh) 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
EP1231273A1 (en) 2001-02-12 2002-08-14 Plant Research International B.V. Terpene synthase/cyclase and olefin synthase and uses thereof
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
IL158322A0 (en) 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
JP2006509038A (ja) 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
EP1572164A2 (en) 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2004296877A1 (en) 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
CA2551946A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
IL162636A0 (en) 2004-06-20 2005-11-20 Yissum Res Dev Co Resorcinol derivatives and their use for lowering blood pressure
CN101076324A (zh) 2004-10-22 2007-11-21 法玛氏公司 口服有效的大麻素类似物
TW200843761A (en) 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP5430929B2 (ja) 2005-06-17 2014-03-05 フイルメニツヒ ソシエテ アノニム 新規セスキテルペン合成酵素ならびにその使用方法
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
AR059035A1 (es) 2006-01-16 2008-03-12 Syngenta Participations Ag Insecticidas derivados de antranilamida
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
KR101575679B1 (ko) 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
GB0624340D0 (en) 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
WO2008118414A1 (en) 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
US20090155392A1 (en) 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009100245A1 (en) 2008-02-05 2009-08-13 Emisphere Technologies Inc. Low dose hmg-coa reductase inhibitor with reduced side effects
US20110137040A1 (en) 2008-08-01 2011-06-09 Lange Josephus H M Synthesis of 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamidine derivatives
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
CN101439074B (zh) 2008-12-11 2012-06-06 深圳海王药业有限公司 苍术总萜醇提取物及其制备方法和用途
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
NZ609356A (en) 2010-11-25 2014-10-31 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
ES2806034T3 (es) 2011-09-29 2021-02-16 Thc Pharm Gmbh The Health Concept Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
ES2554130T3 (es) 2012-05-23 2015-12-16 Tergum S.L. Extracto de terpenos para el tratamiento de la caída del cabello
CN104884065B (zh) 2012-09-21 2019-01-01 强烈治疗剂公司 治疗癌症的方法
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2014134281A1 (en) 2013-02-28 2014-09-04 Full Spectrum Laboratories Limited Biosynthesis of cannabinoids
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
CN105142618A (zh) 2013-03-15 2015-12-09 韩国联合制药株式会社 提供药理及临床效应的莫沙必利每日单次施用缓释制剂
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2015118549A1 (en) 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
CA2845443A1 (en) 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
WO2016205923A1 (en) 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
EP3928776B1 (en) * 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR20190103302A (ko) 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제
US10772837B2 (en) 2017-03-16 2020-09-15 CannTab Therapeutics, Ltd Modified release multi-layer tablet cannabinoid formulations
EA201992247A1 (ru) 2017-03-23 2020-03-24 Ресептор Холдингз, Инк. Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
CA3078549A1 (en) 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
MX2020003330A (es) 2017-10-05 2020-07-28 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140193345A1 (en) 2001-05-23 2014-07-10 Izun Pharmaceuticals Corporation Herbal compositions for the treatment of mucosal lesions
US20080194676A1 (en) * 2001-11-29 2008-08-14 Richat Abbas Formulations for oral administration of cromolyn sodium
US20110092583A1 (en) 2005-11-07 2011-04-21 Murty Pharmaceuticals, Inc. Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery
US20120237570A1 (en) * 2009-12-22 2012-09-20 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20150050373A1 (en) 2012-03-13 2015-02-19 Piramal Enterprises Limited Herbal composition for the treatment of metabolic disorders
US20140209109A1 (en) * 2013-01-30 2014-07-31 Raymond Louis Larson Smokeless THC and Administration Method Thereof
US20150057341A1 (en) * 2013-08-22 2015-02-26 Stephen C. Perry Composition with Pharmacological Effect for Vaporizing and Method
US20150181925A1 (en) * 2013-12-26 2015-07-02 John Turner Herbal smoking blend
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US20150126595A1 (en) * 2014-12-04 2015-05-07 Mary's Medicinals LLC Transdermal cannabinoid formulations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AAPS J, vol. 11, no. 1, March 2009 (2009-03-01), pages 109 - 119
GUINDONHOHMANN, BR J PHARMACOL, vol. 163, no. 7, August 2011 (2011-08-01), pages 1447 - 63
LASTRES-BECKER ET AL., J NEUROCHEM, vol. 84, no. 5, March 2003 (2003-03-01), pages 1097 - 109
OLAH ET AL., SYNTHESIS, 1979, pages 537 - 538
SIERADZAN ET AL., NEUROLOGY, vol. 57, no. 11, 11 December 2001 (2001-12-11), pages 2108 - 11
TRENDS PHARMACOL SCI, vol. 30, no. 8, August 2009 (2009-08-01), pages 411 - 420
WALSH ET AL., BR J PHARMACOL, vol. 160, no. 5, July 2010 (2010-07-01), pages 1234 - 42

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
US11246852B2 (en) 2016-12-02 2022-02-15 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
CN110121337A (zh) * 2017-01-03 2019-08-13 受体控股公司 药用化合物和营养补充剂
EP3565539A4 (en) * 2017-01-03 2020-08-12 Receptor Holdings, Inc. MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS
WO2018129097A1 (en) * 2017-01-03 2018-07-12 Receptor Life Sciences Medicinal compounds and nutritional supplements
EP3600436A4 (en) * 2017-03-23 2020-12-30 Receptor Holdings, Inc. RAPID AND CONTROLLED ADMINISTRATION OF COMPOSITIONS WITH RESTORED SURROUNDING EFFECTS
CN110382007A (zh) * 2017-03-23 2019-10-25 受体控股公司 具有恢复的环境效应的组合物的快速和受控递送
JP2022507730A (ja) * 2018-11-19 2022-01-18 レセプター・ホールディングス・インコーポレイテッド カンナビノイド由来組成物の吸収変動を低減するｎ－アシル化脂肪アミノ酸
US20210393575A1 (en) * 2018-11-19 2021-12-23 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
JP7566336B2 (ja) 2018-11-19 2024-10-15 スポーク・サイエンシズ・インコーポレイテッド カンナビノイド由来組成物の吸収変動を低減するｎ－アシル化脂肪アミノ酸
WO2020106767A1 (en) * 2018-11-19 2020-05-28 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US12303487B2 (en) * 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
WO2020146478A1 (en) * 2019-01-08 2020-07-16 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
WO2020163866A1 (en) * 2019-02-08 2020-08-13 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
EP3920904A4 (en) * 2019-02-08 2022-11-09 Schedule 1 Therapeutics, Inc. COMPOSITIONS CONTAINING CANNABINOIDS AND METHODS OF USE THEREOF
US12252503B2 (en) 2019-07-12 2025-03-18 Canopy Growth Corporation Cannabinoid derivatives
WO2021038029A1 (en) 2019-08-30 2021-03-04 Sakso Loaded granules, their process of production and their uses
EP4349182A2 (en) 2019-08-30 2024-04-10 Evie Sa Loaded granules, their process of production and their uses
US12410123B2 (en) 2020-05-29 2025-09-09 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
WO2023091173A1 (en) * 2021-11-16 2023-05-25 Michael Hudnall Methods of liver disease treatment

Also Published As

Publication number Publication date
KR102393596B1 (ko) 2022-05-04
CN109069475B (zh) 2022-01-28
CN109069475A (zh) 2018-12-21
MX2018012913A (es) 2019-01-30
MX382853B (es) 2025-03-13
JP2023103393A (ja) 2023-07-26
US11129897B2 (en) 2021-09-28
EP3445356A4 (en) 2019-11-20
AU2017252575A8 (en) 2019-07-18
EP3445356A1 (en) 2019-02-27
EP3445356B1 (en) 2021-06-30
JP7671079B2 (ja) 2025-05-01
JP2025108565A (ja) 2025-07-23
MX2021006037A (es) 2021-07-06
US20190117778A1 (en) 2019-04-25
IL290084A (en) 2022-03-01
CL2018002997A1 (es) 2018-12-21
US10588974B2 (en) 2020-03-17
KR20180134402A (ko) 2018-12-18
AU2022201021B2 (en) 2023-12-14
US20240261408A1 (en) 2024-08-08
US20250367295A1 (en) 2025-12-04
US20230075677A1 (en) 2023-03-09
CO2018011299A2 (es) 2018-11-13
EP3928776B1 (en) 2025-11-12
JP7284241B2 (ja) 2023-05-30
BR112018071518A2 (pt) 2019-02-19
IL262505B (en) 2022-02-01
IL262505A (en) 2018-12-31
US20200197521A1 (en) 2020-06-25
JP6983868B2 (ja) 2021-12-17
AU2017252575B2 (en) 2021-11-18
AU2022201021A1 (en) 2022-03-10
AU2017252575A2 (en) 2019-01-31
AU2017252575A1 (en) 2018-11-15
AU2024200704A1 (en) 2024-02-22
CA3021660A1 (en) 2017-10-26
JP2019515031A (ja) 2019-06-06
EP3928776A1 (en) 2021-12-29
JP2022031762A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
AU2022201021B2 (en) Fast-acting plant-based medicinal compounds and nutritional supplements
US20250120939A1 (en) Fast-acting plant-based medicinal compounds and nutritional supplements
US20240000879A1 (en) Herbal compositions with improved bioavailability
US20230293479A1 (en) Medicinal compounds and nutritional supplements

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3021660

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019506612

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018071518

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017252575

Country of ref document: AU

Date of ref document: 20170421

Kind code of ref document: A

Ref document number: 20187033084

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017786760

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017786760

Country of ref document: EP

Effective date: 20181122

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17786760

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112018071518

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181018

WWW Wipo information: withdrawn in national office

Ref document number: 290084

Country of ref document: IL